FDA Approval: In June 2021, the FDA approved semaglutide as a weight loss treatment for individuals with a body mass index (BMI) of 27 and more, including those with a BMI of 30 and higher, especially when linked to weight-related health problems
Morello, noting that fiber delays the absorption of carbohydrates so they dont cause sudden blood sugar spikes
A cluster randomized trial of primary care patients with overweight or obesity found that those using an online program with added support lost significantly more weight (6.8 lbs on average) at 12 months compared to those using only an online program (4.2 lbs) or receiving usual care (2.6 lbs)
Side Effects Both tirzepatide and semaglutide share similar side effects, including nausea, diarrhea, and stomach discomfort
The qualifications include being an adult with a body mass index (BMI) of at least 30 mg/kg or higher, or a BMI of 27 mg/kg or higher, along with a minimum of one weight-related condition such as type 2 diabetes, high blood pressure, or high cholesterol